Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update
January 15, 2021 09:27 ET
|
Biomerica, Inc.
Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 FDA actively reviewing Company’s EUA submission for its...
Biomerica’s Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark
January 12, 2021 08:19 ET
|
Biomerica, Inc.
Biomerica receives first orders and plans to ship tests in coming weeks Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement...
Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment
December 09, 2020 08:19 ET
|
Biomerica, Inc.
Patient enrollment completion anticipated by the end of April 2021InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatmentTherapy seeks to identify...
Biomerica Reports Fiscal 2021 1st Quarter Financial Results
October 16, 2020 09:27 ET
|
Biomerica, Inc.
IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August...
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results
September 01, 2020 08:19 ET
|
Biomerica, Inc.
Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors
August 31, 2020 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
August 12, 2020 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s...
Biomerica Announces Filing of New Three Year Shelf Registration Statement
July 22, 2020 06:39 ET
|
Biomerica, Inc.
IRVINE, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United States...
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
June 29, 2020 21:39 ET
|
Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
June 16, 2020 08:19 ET
|
Biomerica, Inc.
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced...